Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 27 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

The partnership aims to create oral medications targeting Sclerostin, a protein linked to bone metabolism issues in CKD patients. This initiative highlights the urgent need for effective osteoporosis treatments that do not worsen kidney function. The collaboration combines Zydus's drug development expertise with CDRI's research capabilities to address significant health challenges.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 27, 2024, titled "Zydus and CSIR-Central Drug Research Institute Lucknow to develop best-in-class drug for Chronic Kidney Disease induced Osteoporosis".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases